Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

Neil Fleshner, Roger S. Rittmaster, Michael S. Cookson et al.|Contemporary Clinical Trials|2007

Cited by 68